Immune cell therapy for hard-to-treat grade 4 brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new treatment using special immune cells called Vγ9Vδ2 T cells, given directly into the brain fluid. It is for people with a very aggressive grade 4 brain tumor (malignant glioma) that has not gotten better with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a grade 4 malignant brain tumor (called a glioma) in a key area of the brain.
- Standard treatments like surgery, radiation, or chemotherapy have not worked, or you can't have them.
- You are at least 4 years old and can take care of most daily activities (KPS score of 70 or higher).
- Your blood counts, liver, and kidney function are within safe limits.
- You are not pregnant, and you agree to use birth control if you are of childbearing age.
- You are not taking steroids or other immune-suppressing drugs, and you have not had immune cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
This Phase 2 study tests ADCV01, given “on top of” other standard treatment, for newly diagnosed glioblastoma (grade 4 brain tumor). The goal is to see whether it helps patients live longer and safely manage tumor growth.
This trial tests a new immune cell therapy (gamma-delta T cells from a healthy donor) for people with glioblastoma that has come back or gotten worse after standard treatment. It aims to see if these cells can help fight the tumor.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This trial tests a vaccine made from immune cells (dendritic cells) designed to train your body to fight brain tumors like DIPG or glioblastoma. You may qualify if you have one of these tumors, have had standard treatment, and are generally healthy enough for the study.
Hear when a new GBM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.